PLX : Analysis & Opinions

  1. New Data on Biogen's Eloctate - Analyst Blog

    July 8, 2013
    Eloctate is currently under FDA review.
  2. MDCO's Oritavancin Scores in SOLO II - Analyst Blog

    July 3, 2013
    The company will file for US approval later this year.
  3. Affymetrix Upgraded to Neutral - Analyst Blog

    June 26, 2013
    We have upgraded our recommendation for Affymetrix from Underperform to Neutral.
  4. US Exclusivity for Raptor's Procysbi - Analyst Blog

    June 26, 2013
    Raptor Pharmaceutical announced that the FDA has granted orphan drug status to Procysbi
  5. Isis Pharma Up on Phase II Data - Analyst Blog

    June 25, 2013
    ISIS-APOCIIIRx reduced triglyceride levels and increased good cholesterol levels in type II diabetes patients with high triglycerides.
  6. Protalix and Brazil Health Ministry Ink Deal - Analyst Blog

    June 25, 2013
    Protalix signed a supply and technology transfer agreement with Fiocruz for Uplyso for the treatment of Gaucher disease.
  7. Investing In Israel

    July 29, 2010
    Israel offers solid fundamentals with the high-growth potential of a tech economy.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center